Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy

Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL‐rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B‐precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19‐negative monoblastic AML. Complete remission was achieved with myeloid‐directed chemotherapy.

[1]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Borkhardt,et al.  A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia , 2013 .

[3]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[4]  A. Bernasconi,et al.  Lineage switch in childhood acute leukemia: An unusual event with poor outcome , 2012, American journal of hematology.

[5]  P. Menéndez,et al.  Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement , 2011, Leukemia.

[6]  G. Henze,et al.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia , 2011, Leukemia.

[7]  H. Kanegane,et al.  Early lineage switch in an infant acute lymphoblastic leukemia , 2009, International journal of hematology.

[8]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[9]  D. Persons,et al.  Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia. , 2006, Cancer genetics and cytogenetics.

[10]  G. Bhagat,et al.  Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement , 2005, Leukemia & lymphoma.

[11]  P. Hoffmann,et al.  Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.

[12]  M. Krawczuk-Rybak,et al.  A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemia. , 2003, Medical and pediatric oncology.

[13]  P. Hoffmann,et al.  Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.

[14]  A. Cork,et al.  Molecular heterogeneity in acute leukemia lineage switch. , 1989, Blood.

[15]  S. Stass,et al.  Unexpected heterogeneity in acute leukemia: mixed lineages and lineage switch. , 1985, Human pathology.

[16]  C. Pui,et al.  Lineage switch in acute leukemia. , 1984, Blood.

[17]  B. Haynes,et al.  Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Stass,et al.  Phenotypic conversion of acute leukaemia from T‐lymphoblastic to myeloblastic induced by therapy with 2′‐deoxycoformycin , 1983, British journal of haematology.